Tonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapy

Proactive - Interviews for investors

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

15d ago 5:17

MP3•Episode home

Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce a major milestone for the company and for patients: TONMYA is now commercially available by prescription at pharmacies across the United States. TONMYA is a first-in-class, non-opioid analgesic designed specifically for adults with fibromyalgia and is taken once nightly at bedtime. Dr. Lederman told Proactive that this marks a transformative moment for the estimated 10 million Americans living with fibromyalgia, a chronic condition characterized by widespread pain, sleep disturbance, fatigue, and impaired quality of life. TONMYA offers a novel therapeutic option that directly targets the condition’s core, debilitating symptom—chronic pain—while also showing positive effects on associated symptoms. The commercial launch follows a substantial clinical development program, including the recently published RESILIENT Phase 3 trial in Pain Medicine. The study evaluated TONMYA on primary endpoints measuring pain reduction and secondary endpoints assessing overall patient-reported improvement, symptom severity, sleep quality, functional impact, and fatigue. The published findings reinforce TONMYA’s role as a meaningful new option in a field where therapeutic advances have been limited. Regulatory approval incorporated efficacy and safety results from two double-blind, randomized, placebo-controlled Phase 3 trials involving nearly 1,000 patients. In both studies, TONMYA demonstrated a statistically significant reduction in daily pain scores at 14 weeks, meeting the primary endpoint. A higher proportion of patients receiving TONMYA also achieved clinically meaningful pain improvement after three months compared with placebo, underscoring its real-world therapeutic relevance. With its U.S. pharmacy availability now in place, TONMYA becomes a first-in-class, non-opioid option designed to address the multi-dimensional burden of fibromyalgia—and represents a significant step forward for patients seeking relief and improved daily functioning. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #Tnx-1500 #transplant #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

606 episodes

#Trading #Business News #Business #News #Proactive Investors #Gold #Cannabis #Battery Metals #Chief Executive #Biotech #Natural Resources #Bitcoin #Cryptocurrency #Interviews #Investing #Investment Research #Mining #Retail Investment #Technology